Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell

Prostate

Volumn 73, Issue 9, 2013, Pages 941-951

  Benelli, Roberto ^a   Stigliani, Sara ^a   Minghelli, Simona ^b   Carlone, Sebastiano ^a   Ferrari, Nicoletta ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

chemokine; CXCL1; CXCR2; invasion; prostate cancer; senescence; TRAMP

Indexed keywords

CXCL1 CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER MODEL; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL AGING; CELL GROWTH PROCESSES; CHEMOKINE CXCL1; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84878284676     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22640     Document Type: Article

References (33)

1. Mantovani A, Bonecchi R, Locati M,. Tuning inflammation and immunity by chemokine sequestration: Decoys and more. Nat Rev 2006; 6: 907-918.
2. Rollins BJ,. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760-767.
3. Keane MP, Arenberg DA, Moore BB, Addison CL, Strieter RM,. CXC chemokines and angiogenesis/angiostasis. Proc Assoc Am Phys 1998; 110: 288-296.
4. Richmond A, Lawson DH, Nixon DW, Chawla RK,. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res 1985; 45: 6390-6394.
5. Richmond A, Balentien E, Thomas HG, Flaggs G, Barton DE, Spiess J, Bordoni R, Francke U, Derynck R,. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J 1988; 7: 2025-2033.
6. Dhawan P, Richmond A,. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
7. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL,. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-167.
8. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA,. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005; 64: 40-49.
9. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, Vessella RL, Ralph D,. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 1999; 53: 139-147.
10. Begley LA, Kasina S, MacDonald J, Macoska JA,. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43: 194-199.
11. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J,. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133: 1006-1018.
12. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM,. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol 1999; 154: 1503-1512.
13. Frankenberry KA, Somasundar P, McFadden DW, Vona-Davis LC,. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 2004; 188: 560-565.
14. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM,. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330.
15. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR,. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
16. Larghero P, Vene R, Minghelli S, Travaini G, Morini M, Ferrari N, Pfeffer U, Noonan DM, Albini A, Benelli R,. Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis 2007; 28: 1008-1020.
17. Acosta JC, O'Loghlen A, Banito A, Raguz S, Gil J,. Control of senescence by CXCR2 and its ligands. Cell Cycle 2008; 7: 2956-2959.
18. Acosta JC, Gil J,. A role for CXCR2 in senescence, but what about in cancer? Cancer Res 2009; 69: 2167-2170.
19. Wang C, Jurk D, Maddick M, Nelson G, Martin-Ruiz C, von Zglinicki T,. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 2009; 8: 311-323.
20. Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV,. Androgen receptor drives cellular senescence. PLoS ONE 7 (3): e31052.
21. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA,. CXCL5 promotes prostate cancer progression. Neoplasia 2008; 10: 244-254.
22. Waugh DJ, Wilson C, Seaton A, Maxwell PJ,. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 2008; 13: 4595-4604.
23. Reiland J, Furcht LT, McCarthy JB,. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999; 41: 78-88.
24. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP,. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000; 6: 2104-2119.
25. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ,. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001; 3: 33-42.
26. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ,. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 2001; 61: 2533-2536.
27. Sugamoto T, Tanji N, Sato K, Fujita H, Nishio S, Sakanaka M, Yokoyama M,. The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: Correlation with neovascularization. Anticancer Res 2001; 21: 77-88.
28. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI,. Characterization of two high affinity human interleukin-8 receptors. J Biol Chem 1992; 267: 16283-16287.
29. Campisi J,. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11: S27-S31.
30. Acosta JC, Gil J,. Senescence: A new weapon for cancer therapy. Trends Cell Biol 2012; 22: 211-219.
31. Bissell MJ, Hines WC,. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-329.
32. Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE, Benson MC,. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 2000; 56: 160-166.
33. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR,. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008; 14: 146-155.